In the originally published article titled “Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review”, published in “Current Diabetes Reviews”, Vol: 21, 2025 1, certain phrases and expressions were unclear, which may have affected readability. These have now been revised to improve clarity and ensure that the intended meaning is accurately conveyed. The corrections do not affect the results, interpretations, or conclusions of the article. We apologize for any inconvenience caused and appreciate the opportunity to rectify this matter. The original article can be found online at https://www.eurekaselect.com/article/140414 Original: 4.1.3. GLP-1 Receptor Agonist According to the latest press release, DD01 is therapeutic against hepatic steatosis and lowers body weight in T2DM patients diagnosed with or without fatty liver ailment. Corrected: 4.1.3. GLP-1 Receptor Agonist According to the latest press release, DD01 is therapeutic against hepatic steatosis and lowers body weight in T2DM patients diagnosed with or without fatty liver disorder.
Tiwari et al. (2026) studied this question.